KRAS gene mutations in lung cancer: Particulars established and issues unresolved

Pathology International

Volumn 60, Issue 10, 2010, Pages 651-660

  Okudela, Koji ^a   Woo, Tetsukan ^a   Kitamura, Hitoshi ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

carcinogenesis; KRAS; lung cancer

Indexed keywords

ERLOTINIB; GEFITINIB; K RAS PROTEIN;

ADENOCARCINOMA; AMINO ACID SEQUENCE; CANCER INHIBITION; CARCINOGENESIS; CODON; DNA METHYLATION; EPITHELIUM CELL; GENE MUTATION; HISTOPATHOLOGY; LUNG CANCER; MOLECULARLY TARGETED THERAPY; NUCLEOTIDE SEQUENCE; POINT MUTATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; TREATMENT RESPONSE;

CARCINOMA; HUMANS; LUNG NEOPLASMS; MUTATION; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 77956805993     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2010.02580.x     Document Type: Review

References (95)

1. Kitamura H, Kameda Y, Ito T, Hayashi H. Atypical adenomatous hyperplasia of the lung. Implications for the pathogenesis of peripheral lung adenocarcinoma. Am J Clin Pathol 2000 113 : 610 20.
2. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, eds. World Health Organization Classification of Tumors. Pathology and Genetics of the Lung, Pleura, Thymus and Heart.
3. Kumar V, Cotran RS, Robbins SL. Basic Pathology, 5th edn.
4. Santos E, Martin-Zanca D, Reddy EP, Pierotti MA, Della Porta G, Barbacid M. Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science 1984 223 : 661 4.
5. Rodenhuis S, van de Wetering ML, Mooi WJ, Evers SG, van Zandwijk N, Bos JL. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 1987 317 : 929 35.
6. Kitamura H, Yazawa T, Okudela K, Shimoyamada H, Sato H. Molecular and genetic pathogenesis of lung cancer: Difference between small cell and non small cell carcinomas. Open Pathol J 2008 2 : 106 14.
7. Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 2009 6 : 201 5.
8. Okudela K, Hayashi H, Ito T et al. K-ras gene mutation enhances motility of immortalized airway cells and lung adenocarcinoma cells via Akt activation: Possible contribution to non-invasive expansion of lung adenocarcinoma. Am J Pathol 2004 164 : 91 100.
9. Okudela K, Yazawa T, Woo T et al. Down-regulation of DUSP6 expression in lung cancer: Its mechanism and potential role in carcinogenesis. Am J Pathol 2009 175 : 867 81.
10. Okudela K, Yazawa T, Ishii J et al. Down-regulation of FXYD3 expression in human lung cancers: Its mechanism and potential role in carcinogenesis. Am J Pathol 2009 175 : 2646 56.
11. Okudela K, Woo T, Mitsui H et al. Morphometric profiling of lung cancers-its association with clinicopathologic, biologic, and molecular genetic features. Am J Surg Pathol 2010 34 : 243 55.
12. Woo T, Okudela K, Yazawa T et al. Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas. Lung Cancer 2009 65 : 355 62.
13. Harvey JJ. An unidentified virus which causes the rapid production of tumors in mice. Nature 1964 204 : 1104 5.
14. Kirsten WH, Mayer LA. Morphologic responses to a murine erythroblastosis virus. J Natl Cancer Inst 1967 39 : 311 35.
15. Goldfarb M, Shimizu K, Perucho M, Wigler M. Isolation and preliminary characterization of a human transforming gene from T24 bladder carcinoma cells. Nature 1982 296 : 404 9.
16. Pulciani S, Santos E, Lauver AV, Long LK, Robbins KC, Barbacid M. Oncogenes in human tumor cell lines: Molecular cloning of a transforming gene from human bladder carcinoma cells. Proc Natl Acad Sci USA 1982 79 : 2845 9.
17. Pulciani S, Santos E, Lauver AV, Long LK, Barbacid M. Transforming genes in human tumors. J Cell Biochem 1982 20 : 51 61.
18. Shih C, Padhy LC, Murray M, Weinberg RA. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 1981 261 4.
19. Hall A, Marshall CJ, Spurr NK, Weiss RA. Identification of transforming gene in two human sarcoma cell lines as a new member of the ras gene family located on chromosome 1. Nature 1983 303 : 396 400.
20. Shimizu K, Goldfarb M, Perucho M, Wigler M. Isolation and preliminary characterization of the transforming gene of a human neuroblastoma cell line. Proc Natl Acad Sci USA 1983 80 : 383 7.
21. Lowe DG, Capon DJ, Delwart E, Sakaguchi AY, Naylor SL, Goeddel DV. Structure of the human and murine R-ras genes, novel genes closely related to ras proto-oncogenes. Cell 1987 48 : 137 46.
22. Louahed J, Grasso L, De Smet C et al. Interleukin-9-induced expression of M-Ras/R-Ras3 oncogene in T-helper clones. Blood 1999 94 : 1701 10.
23. Matsumoto K, Asano T, Endo T. Novel small GTPase M-Ras participates in reorganization of actin cytoskeleton. Oncogene 1997 15 : 2409 17.
24. Downward J. Ras signalling and apoptosis. Curr Opin Genet Dev 1998 8 : 49 54.
25. Downward J. Signal transduction. New exchange, new target. Nature 1998 396 : 416 17.
26. Vojtek AB, Der CJ. Increasing complexity of the Ras signaling pathway. J Biol Chem 1998 273 : 19925 8.
27. Reddy EP, Reynolds RK, Santos E, Barbacid M. A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature 1982 300 : 149 52.
28. Tabin CJ, Bradley SM, Bargmann CI et al. Mechanism of activation of a human oncogene. Nature 1982 300 : 143 9.
29. Taparowsky E, Suard Y, Fasano O, Shimizu K, Goldfarb M, Wigler M. Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change. Nature 1982 300 : 762 5.
30. Porta M, Crous-Bou M, Wark PA, Vineis P, Real FX, Malats N, Kampman E. Cigarette smoking and K-ras mutations in pancreas, lung and colorectal adenocarcinomas: etiopathogenic similarities, differences and paradoxes. Mutat Res 2009 682 : 83 93.
31. Forbes S, Clements J, Dawson E et al. COSMIC 2005. Br J Cancer 2006 94 : 318 22.
32. Brose MS, Volpe P, Feldman M et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002 62 : 6997 7000.
33. Suzuki Y, Orita M, Shiraishi M, Hayashi K, Sekiya T. Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 1990 5 : 1037 43.
34. Marchetti A, Buttitta F, Pellegrini S et al. Bronchioloalveolar lung carcinomas: K-ras mutations are constant events in the mucinous subtype. J Pathol 1996 179 : 254 9.
35. Maeshima A, Sakamoto M, Hirohashi S. Mixed mucinous-type and non-mucinous-type adenocarcinoma of the lung:immunohistochemical examination and K- ras gene mutation. Virchows Arch 2002 440 : 598 603.
36. Sakuma Y, Matsukuma S, Yoshihara M et al. Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: Confirmation of the correlations with histologic subtypes and gene mutations. Am J Clin Pathol 2007 128 : 100 108.
37. Suzuki M, Shigematsu H, Iizasa T et al. Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of non-small cell lung cancer. Cancer 2006 106 : 2200 207.
38. Okudela K, Woo T, Yazawa T et al. Significant association between EGFR-mutated lung adenocarcinoma and past illness from gastric cancer or uterine myoma: Its implication in carcinogenesis. Lung Cancer 2009 66 : 287 91.
39. Kosaka T, Yatabe Y, Onozato R, Kuwano H, Mitsudomi T. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol 2009 4 : 22 9.
40. Bell DW, Brannigan BW, Matsuo K et al. Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: Analysis of estrogen-related polymorphisms. Clin Cancer Res 2008 14 : 4079 84.
41. Gazdar AF, Miyajima K, Reddy J et al. Molecular targets for cancer therapy and prevention. Chest 2004 125 : 97S 101S.
42. Gazdar AF, Shigematsu H, Herz J, Minna JD. Mutations and addiction to EGFR: The Achilles 'heal' of lung cancers? Trends Mol Med 2004 10 : 481 6.
43. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004 101 : 13306 11.
44. Pao W, Wang TY, Riely GJ et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005 2 : e17.
45. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006 118 : 257 62.
46. Pham D, Kris MG, Riely GJ et al. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol 2006 24 : 1700 704.
47. Suzuki M, Shigematsu H, Nakajima T et al. Synchronous alterations of Wnt and epidermal growth factor receptor signaling pathways through aberrant methylation and mutation in non small cell lung cancer. Clin Cancer Res 2007 13 : 6087 92.
48. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007 98 : 1817 24.
49. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004 350 : 2129 39.
50. Tsao MS, Aviel-Ronen S, Ding K et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol 2007 25 : 5240 47.
51. Winton T, Livingston R, Johnson D et al. National Cancer Instituteof Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005 352 : 2589 97.
52. Marks JL, Broderick S, Zhou Q et al. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol 2008 3 : 111 16.
53. Mascaux C, Iannino N, Martin B et al. The role of RAS oncogene in survival of patients with lung cancer: A systematic review of the literature with meta-analysis. Br J Cancer 2005 92 : 131 9.
54. Loriot Y, Mordant P, Deutsch E, Olaussen KA, Soria JC. Are RAS mutations predictive markers of resistance to standard chemotherapy? Nat Rev Clin Oncol 2009 6 : 528 34.
55. Kloog Y, Cox AD. RAS inhibitors: Potential for cancer therapeutics. Mol Med Today 2000 6 : 398 402.
56. Blum R, Cox AD, Kloog Y. Inhibitors of chronically active ras: Potential for treatment of human malignancies. Recent Pat Anticancer Drug Discov 2008 3 : 31 47.
57. Kitamura H, Kameda Y, Nakamura N et al. Proliferative potential and p53 overexpression in precursor and early stage lesions of bronchioloalveolar lung carcinoma. Am J Pathol 1995 146 : 876 87.
58. Kitamura H, Kameda Y, Nakamura N et al. Atypical adenomatous hyperplasia and bronchoalveolar lung carcinoma. Analysis by morphometry and the expressions of p53 and carcinoembryonic antigen. Am J Surg Pathol 1996 20 : 553 62.
59. Niho S, Yokose T, Suzuki K, Kodama T, Nishiwaki Y, Mukai K. Monoclonality of atypical adenomatous hyperplasia of the lung. Am J Pathol 1999 154 : 249 54.
60. Sato M, Vaughan MB, Girard L et al. Multiple oncogenic changes (K-RAS (V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res 2006 66 : 2116 28.
61. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997 88 : 593 602.
62. Huot TJ, Rowe J, Harland M et al. Biallelic mutations in p16 (INK4a) confer resistance to Ras- and Ets-induced senescence in human diploid fibroblasts. Mol Cell Biol 2002 22 : 8135 43.
63. Marcotte R, Wang E. Replicative senescence revisited. Gerontol A Biol Sci Med Sci 2002 57 : B257 69.
64. Chi S, Kitanaka C, Noguchi K et al. Oncogenic Ras triggers cell suicide through the activation of a caspase-independent cell death program in human cancer cells. Oncogene 1999 18 : 2281 90.
65. Kitanaka C, Kuchino Y. Caspase-independent programmed cell death with necrotic morphology. Cell Death Differ 1999 6 : 508 15.
66. Cagnol S, Chambard JC. ERK and cell death: Mechanisms of ERK-induced cell death - apoptosis, autophagy and senescence. FEBS J 2010 277 : 2 21.
67. Cammarano MS, Nekrasova T, Noel B, Minden A. Pak4 induces premature senescence via a pathway requiring p16INK4/p19ARF and mitogen-activated protein kinase signaling. Mol Cell Biol 2005 25 : 9532 42.
68. Wang W, Chen JX, Liao R et al. Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6-p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence. Mol Cell Biol 2002 22 : 3389 403.
69. Lin AW, Barradas M, Stone JC, van Aelst L, Serrano M, Lowe SW. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev 1998 12 : 3008 19.
70. Maiuri MC, Le Toumelin G, Criollo A et al. Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. EMBO J 2007 26 : 2527 39.
71. Maiuri MC, Criollo A, Tasdemir E et al. BH3-only proteins and BH3 mimetics induce autophagy by competitively disrupting the interaction between Beclin 1 and Bcl-2/Bcl-X(L). Autophagy 2007 3 : 374 6.
72. Fernandez C, Ramos AM, Sancho P, Amran D, de Blas E, Aller P. 12-O-tetradecanoylphorbol-13-acetate may both potentiate and decrease the generation of apoptosis by the antileukemic agent arsenic trioxide in human promonocytic cells. Regulation by extracellular signal-regulated protein kinases and glutathione. J Biol Chem 2004 279 : 3877 84.
73. Lee ER, Kim JY, Kang YJ et al. Interplay between PI3K/Akt and MAPK signaling pathways in DNA-damaging drug-induced apoptosis. Biochim Biophys Acta 2006 1763 : 958 68.
74. Panaretakis T, Hjortsberg L, Tamm KP et al. Interferon alpha induces nucleus-independent apoptosis by activating extracellular signal-regulated kinase 1/2 and c-Jun NH2-terminal kinase downstream of phosphatidylinositol 3-kinase and mammalian target of rapamycin. Mol Biol Cell 2008 19 : 41 50.
75. Cheng Y, Qiu F, Tashiro S, Onodera S, Ikejima T. ERK and JNK mediate TNFalpha-induced p53 activation in apoptotic and autophagic L929 cell death. Biochem Biophys Res Commun 2008 376 : 483 8.
76. Sivaprasad U, Basu A. Inhibition of ERK attenuates autophagy and potentiates tumour necrosis factor-alpha-induced cell death in MCF-7 cells. J Cell Mol Med 2008 12 : 1265 71.
77. DeNicola GM, Tuveson DA. RAS in cellular transformation and senescence. Eur J Cancer 2009 45 : 211 16.
78. Kerr JF. History of the events leading to the formulation of the apoptosis concept. Toxicology 2002 181-182 : 471 4.
79. Zhu J, Woods D, McMahon M, Bishop JM. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev 1998 12 : 2997 3007.
80. Ferbeyre G, de Stanchina E, Lin AW et al. Oncogenic ras and p53 cooperate to induce cellular senescence. Mol Cell Biol 2002 22 : 3497 508.
81. An HJ, Maeng O, Kang KH et al. Activation of Ras up-regulates pro-apoptotic BNIP3 in nitric oxide-induced celldeath. J Biol Chem 2006 281 : 33939 48.
82. Minoo P, Jass JR. Senescence and serration: a new twist to an old tale. J Pathol 2006 210 : 137 40.
83. Oh SH, Lim SC. Endoplasmic reticulum stress-mediated autophagy/apoptosis induced by capsaicin (8-methyl-N-vanillyl-6-nonenamide) and dihydrocapsaicin is regulated by the extent of c-Jun NH2-terminal kinase/extracellular signal-regulated kinase activation in WI38 lung epithelial fibroblast cells. J Pharmacol Exp Ther 2009 329 : 112 22.
84. Di Micco R, Fumagalli M, Cicalese A et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006 444 : 638 42.
85. Levine AJ. The common mechanisms of transformation by the small DNA tumor viruses: The inactivation of tumor suppressor gene products: p53. Virology 2009 384 : 285 93.
86. Abbaszadegan RM, Afsharnezhad S, Raziee HR, Ghafarzadegan K, Ghavamnasiry MR. p16/INK4a promoter hypermethylation in serum, blood and tumor of patients with esophageal squamous cell carcinoma. IJBMS 2004 4 : 2 8.
87. Okudela K, Suzuki M, Kageyama S et al. PIK3CA mutation and amplification in human lung cancer. Pathol Int 2007 57 : 664 71.
88. Sarkisian CJ, Keister BA, Stairs DB, Boxer RB, Moody SE, Chodosh LA. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol 2007 9 : 493 505.
89. Tuveson DA, Shaw AT, Willis NA et al. Endogenous oncogenic K-ras (G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 2004 5 : 375 87.
90. Ward R, Hawkins N, O'Grady R et al. Restriction endonuclease-mediated selective polymerase chain reaction. Am J Pathol 1998 153 : 373 9.
91. Imai T, Yasuhara K, Tamura T et al. Inhibitory effects of cinnamaldehyde on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung carcinogenesis in rasH2 mice. Cancer Lett 2002 175 : 9 16.
92. Moghaddam SJ, Li H, Cho SN et al. Promotion of lung carcinogenesis by chronic obstructive pulmonary disease-like airway inflammation in a K-ras-induced mouse model. Am J Respir Cell Mol Biol 2009 40 : 443 53.
93. Jackson EL, Willis N, Mercer K et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001 15 : 3243 8.
94. Sato H, Yazawa T, Suzuki T et al. Growth regulation via insulin-like growth factor binding protein-4 and -2 in association with mutant K-ras in lung epithelia. Am J Pathol 2006 169 : 1550 66.
95. Cozens AL, Yezzi MJ, Kunzelmann K et al. CFTR expression and chloride secretion in polarized immortal human bronchial epithelial cells. Am J Respir Cell Mol Biol 1994 10 : 38 47.